Domingo Esteban, Carla(Universitat Politècnica de València, 2023-11-20)
[EN] Triple-negative breast cancers (TNBC) with poor response to neoadjuvant chemotherapy present a potential target, EZH2, for pharmacological intervention with tazemetostat. Tazemetostat is an FDA-approved EZH2 inhibitor ...